Crohn’s Disease: MORF-057 Treatment Study

We are testing a new medication, MORF-057, for adults with moderately to severely active Crohn’s disease. The study aims to see if it improves symptoms and endoscopic results compared to a placebo.

1-2 years 6-10 visits Efficacy phase (II)Post-Trial Drug Access Investigational Medicines OralGastroenterologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Moroctocog Alfa

Moroctocog alfa is a clotting factor VIII replacement used to prevent and control bleeding in people with hemophilia A.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Morf-057

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Medizinische Universitaet Innsbruck

University Hospital for Internal Medicine I

Innsbruck, Austria

Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH

Department of Internal Medicine I

Salzburg, Austria

Noe LGA Gesundheit Region Mitte GmbH

Univ. Hospital St. Poelten, Dep. of Internal Medicine II, Div. of Gastroenterology and Hepatology

Sankt Pölten, Austria

Sponsor: Morphic Therapeutic Inc.

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.